Chronic graft-versus-host disease: biological insights from preclinical and clinical studies
Tóm tắt
With the increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor–mobilized peripheral blood stem cell donor grafts and successful treatment of older recipients, chronic graft-versus-host disease (cGVHD) has emerged as the major cause of nonrelapse mortality and morbidity. cGVHD is characterized by lichenoid changes and fibrosis that affects a multitude of tissues, compromising organ function. Beyond steroids, effective treatment options are limited. Thus, new strategies to both prevent and treat disease are urgently required. Over the last 5 years, our understanding of cGVHD pathogenesis and basic biology, born out of a combination of mouse models and correlative clinical studies, has radically improved. We now understand that cGVHD is initiated by naive T cells, differentiating predominantly within highly inflammatory T-helper 17/T-cytotoxic 17 and T-follicular helper paradigms with consequent thymic damage and impaired donor antigen presentation in the periphery. This leads to aberrant T- and B-cell activation and differentiation, which cooperate to generate antibody-secreting cells that cause the deposition of antibodies to polymorphic recipient antigens (ie, alloantibody) or nonpolymorphic antigens common to both recipient and donor (ie, autoantibody). It is now clear that alloantibody can, in concert with colony-stimulating factor 1 (CSF-1)-dependent donor macrophages, induce a transforming growth factor β–high environment locally within target tissue that results in scleroderma and bronchiolitis obliterans, diagnostic features of cGVHD. These findings have yielded a raft of potential new therapeutics, centered on naive T-cell depletion, interleukin-17/21 inhibition, kinase inhibition, regulatory T-cell restoration, and CSF-1 inhibition. This new understanding of cGVHD finally gives hope that effective therapies are imminent for this devastating transplant complication.
Tài liệu tham khảo
Flowers, 2015, How we treat chronic graft-versus-host disease, Blood, 125, 606, 10.1182/blood-2014-08-551994
Martin, 2010, Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation, J Clin Oncol, 28, 1011, 10.1200/JCO.2009.25.6693
Wingard, 2011, Long-term survival and late deaths after allogeneic hematopoietic cell transplantation, J Clin Oncol, 29, 2230, 10.1200/JCO.2010.33.7212
Arai, 2011, Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria, Blood, 118, 4242, 10.1182/blood-2011-03-344390
Jacobsohn, 2012, Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium, Blood, 120, 2545, 10.1182/blood-2012-04-424135
Shulman, 2015, NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report, Biol Blood Marrow Transplant, 21, 589, 10.1016/j.bbmt.2014.12.031
Martin, 2015, National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report, Biol Blood Marrow Transplant, 21, 1343, 10.1016/j.bbmt.2015.05.004
Blazar, 2012, Advances in graft-versus-host disease biology and therapy, Nat Rev Immunol, 12, 443, 10.1038/nri3212
Chu, 2008, Murine models of chronic graft-versus-host disease: insights and unresolved issues, Biol Blood Marrow Transplant, 14, 365, 10.1016/j.bbmt.2007.12.002
McDonald-Hyman, 2015, Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation, Sci Transl Med, 7, 280rv2, 10.1126/scitranslmed.aaa6853
Schroeder, 2011, Mouse models of graft-versus-host disease: advances and limitations, Dis Model Mech, 4, 318, 10.1242/dmm.006668
Shlomchik, 2007, Transplantation’s greatest challenges: advances in chronic graft-versus-host disease, Biol Blood Marrow Transplant, 13, 2, 10.1016/j.bbmt.2006.10.020
Socié, 2014, Current issues in chronic graft-versus-host disease, Blood, 124, 374, 10.1182/blood-2014-01-514752
Jagasia, 2015, National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report, Biol Blood Marrow Transplant, 21, 389, 10.1016/j.bbmt.2014.12.001
Arpinati, 2000, Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells, Blood, 95, 2484, 10.1182/blood.V95.8.2484
Morris, 2004, Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance, Blood, 103, 3573, 10.1182/blood-2003-08-2864
Pan, 1995, Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease, Blood, 86, 4422, 10.1182/blood.V86.12.4422.bloodjournal86124422
Anasetti, 2012, Peripheral-blood stem cells versus bone marrow from unrelated donors, N Engl J Med, 367, 1487, 10.1056/NEJMoa1203517
Stem Cell Trialists’ Collaborative Group, 2005, Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials, J Clin Oncol, 23, 5074, 10.1200/JCO.2005.09.020
Flowers, 2011, Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria, Blood, 117, 3214, 10.1182/blood-2010-08-302109
Chen, 2007, Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease, Blood, 110, 3804, 10.1182/blood-2007-05-091074
Anderson, 2004, Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease, Blood, 104, 1565, 10.1182/blood-2004-01-0328
Tivol, 2005, Emergent autoimmunity in graft-versus-host disease, Blood, 105, 4885, 10.1182/blood-2004-12-4980
Zhang, 2007, CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease, J Immunol, 179, 3305, 10.4049/jimmunol.179.5.3305
Panoskaltsis-Mortari, 2007, A new murine model for bronchiolitis obliterans post-bone marrow transplant, Am J Respir Crit Care Med, 176, 713, 10.1164/rccm.200702-335OC
Srinivasan, 2012, Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans, Blood, 119, 1570, 10.1182/blood-2011-07-364414
Wu, 2013, Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells, J Immunol, 191, 488, 10.4049/jimmunol.1300657
Hill, 2010, Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma, Blood, 116, 819, 10.1182/blood-2009-11-256495
Flynn, 2014, Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans, Blood, 123, 3988, 10.1182/blood-2014-03-562231
Reddy, 2008, Mouse models of bone marrow transplantation, Biol Blood Marrow Transplant, 14, 129, 10.1016/j.bbmt.2007.10.021
Baker, 1997, Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function, Proc Natl Acad Sci USA, 94, 1366, 10.1073/pnas.94.4.1366
Garvy, 1993, Suppression of B-cell development as a result of selective expansion of donor T cells during the minor H antigen graft-versus-host reaction, Blood, 82, 2758, 10.1182/blood.V82.9.2758.2758
Storek, 2001, Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation, Blood, 98, 489, 10.1182/blood.V98.2.489
Krenger, 2008, The immunopathology of thymic GVHD, Semin Immunopathol, 30, 439, 10.1007/s00281-008-0131-6
van den Brink, 2000, Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity, Transplantation, 69, 446, 10.1097/00007890-200002150-00026
Dertschnig, 2015, Impaired thymic expression of tissue-restricted antigens licenses the de novo generation of autoreactive CD4+ T cells in acute GVHD, Blood, 125, 2720, 10.1182/blood-2014-08-597245
Holländer, 1994, Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease, J Immunol, 152, 1609, 10.4049/jimmunol.152.4.1609
Sakoda, 2007, Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease, Blood, 109, 1756, 10.1182/blood-2006-08-042853
Ivanov, 2009, Induction of intestinal Th17 cells by segmented filamentous bacteria, Cell, 139, 485, 10.1016/j.cell.2009.09.033
Bennett, 1998, Cytokine and cytotoxic pathways of NK cell rejection of class I-deficient bone marrow grafts: influence of mouse colony environment, Int Immunol, 10, 785, 10.1093/intimm/10.6.785
Beura, 2016, Normalizing the environment recapitulates adult human immune traits in laboratory mice, Nature, 532, 512, 10.1038/nature17655
Jenq, 2012, Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation, J Exp Med, 209, 903, 10.1084/jem.20112408
Mathewson, 2016, Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease, Nat Immunol, 17, 505, 10.1038/ni.3400
Shono, 2016, Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice, Sci Transl Med, 8, 339ra71, 10.1126/scitranslmed.aaf2311
Ordemann, 2002, Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease, J Clin Invest, 109, 1249, 10.1172/JCI0214793
Toubai, 2012, Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells, Blood, 119, 3844, 10.1182/blood-2011-10-384057
Miklos, 2005, Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission, Blood, 105, 2973, 10.1182/blood-2004-09-3660
Zorn, 2004, Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation, J Exp Med, 199, 1133, 10.1084/jem.20031560
Hill, 2000, The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation, Blood, 95, 2754, 10.1182/blood.V95.9.2754.009k25_2754_2759
Gartlan, 2015, Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects, Blood, 126, 1609, 10.1182/blood-2015-01-622662
Kappel, 2009, IL-17 contributes to CD4-mediated graft-versus-host disease, Blood, 113, 945, 10.1182/blood-2008-08-172155
Yi, 2009, Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease, Blood, 114, 3101, 10.1182/blood-2009-05-219402
Carlson, 2009, In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations, Blood, 113, 1365, 10.1182/blood-2008-06-162420
Matte-Martone, 2010, Recipient B cells are not required for graft-versus-host disease induction, Biol Blood Marrow Transplant, 16, 1222, 10.1016/j.bbmt.2010.03.015
Rowe, 2006, Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation, Blood, 108, 2485, 10.1182/blood-2006-04-016063
Weber, 2014, Donor and host B cell-derived IL-10 contributes to suppression of graft-versus-host disease, Eur J Immunol, 44, 1857, 10.1002/eji.201344081
Anderson, 2003, Memory CD4+ T cells do not induce graft-versus-host disease, J Clin Invest, 112, 101, 10.1172/JCI17601
Bleakley, 2015, Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts, J Clin Invest, 125, 2677, 10.1172/JCI81229
Weinberg, 2001, Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation, Blood, 97, 1458, 10.1182/blood.V97.5.1458
Markey, 2012, Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subsets, Blood, 119, 5918, 10.1182/blood-2011-12-398164
Coghill, 2011, Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new, Blood, 117, 3268, 10.1182/blood-2010-12-290403
Allen, 1993, Differential cytokine expression in acute and chronic murine graft-versus-host-disease, Eur J Immunol, 23, 333, 10.1002/eji.1830230205
Via, 1994, IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease, J Immunol, 153, 4040, 10.4049/jimmunol.153.9.4040
Murphy, 1998, Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice, J Clin Invest, 102, 1742, 10.1172/JCI3906
Ochs, 1996, Cytokine expression in human cutaneous chronic graft-versus-host disease, Bone Marrow Transplant, 17, 1085
Steinman, 2007, A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage, Nat Med, 13, 139, 10.1038/nm1551
Murata, 2008, Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?, J Dermatol Sci, 50, 240, 10.1016/j.jdermsci.2008.01.001
Yoshizaki, 2010, Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model, J Immunol, 185, 2502, 10.4049/jimmunol.0901778
Li, 2016, Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease, JCI Insight, 1, 10.1172/jci.insight.86660
Dander, 2009, Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation, Transplantation, 88, 1261, 10.1097/TP.0b013e3181bc267e
Serody, 2012, The IL-17 differentiation pathway and its role in transplant outcome, Biol Blood Marrow Transplant, 18, S56, 10.1016/j.bbmt.2011.10.001
Brüggen, 2014, Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease, Blood, 123, 290, 10.1182/blood-2013-07-514372
Flynn, 2016, Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism, Blood, 127, 2144, 10.1182/blood-2015-10-678706
Lu, 2014, Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions, Proc Natl Acad Sci USA, 111, E3432, 10.1073/pnas.1408780111
Varelias, 2015, Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation, Blood, 125, 2435, 10.1182/blood-2014-07-590232
Kennedy, 2014, Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial, Lancet Oncol, 15, 1451, 10.1016/S1470-2045(14)71017-4
Harris, 2007, Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity, J Immunol, 179, 4313, 10.4049/jimmunol.179.7.4313
Radojcic, 2010, STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model, J Immunol, 184, 764, 10.4049/jimmunol.0903006
Broady, 2010, Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells, Blood, 116, 5748, 10.1182/blood-2010-07-295436
Kara, 2015, CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells, Nat Commun, 6, 8644, 10.1038/ncomms9644
Muranski, 2013, Essentials of Th17 cell commitment and plasticity, Blood, 121, 2402, 10.1182/blood-2012-09-378653
Yeh, 2010, Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype, J Immunol, 185, 2089, 10.4049/jimmunol.1000818
Yen, 2009, Tc17 CD8 T cells: functional plasticity and subset diversity, J Immunol, 183, 7161, 10.4049/jimmunol.0900368
Croudace, 2012, Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD, Blood, 120, 4246, 10.1182/blood-2012-02-413260
Kitko, 2014, Plasma CXCL9 elevations correlate with chronic GVHD diagnosis, Blood, 123, 786, 10.1182/blood-2013-08-520072
Byersdorfer, 2013, Effector T cells require fatty acid metabolism during murine graft-versus-host disease, Blood, 122, 3230, 10.1182/blood-2013-04-495515
Gatza, 2011, Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease, Sci Transl Med, 3, 67ra8, 10.1126/scitranslmed.3001975
Marcondes, 2014, α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics, Blood, 124, 2881, 10.1182/blood-2014-04-570440
Nguyen, 2016, Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation, J Clin Invest, 126, 1337, 10.1172/JCI82587
Saha, 2013, Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality, Blood, 122, 3062, 10.1182/blood-2013-05-500801
Greinix, 2008, Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease, Biol Blood Marrow Transplant, 14, 208, 10.1016/j.bbmt.2007.10.009
Corre, 2010, Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections, Haematologica, 95, 1025, 10.3324/haematol.2009.018853
Allen, 2012, B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways, Blood, 120, 2529, 10.1182/blood-2012-06-438911
Tedder, 2015, B10 cells: a functionally defined regulatory B cell subset, J Immunol, 194, 1395, 10.4049/jimmunol.1401329
Khoder, 2014, Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD, Blood, 124, 2034, 10.1182/blood-2014-04-571125
Le Huu, 2013, Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease, Blood, 121, 3274, 10.1182/blood-2012-11-465658
de Masson, 2015, CD24(hi)CD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease, Blood, 125, 1830, 10.1182/blood-2014-09-599159
Fujii, 2008, Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group, Blood, 111, 3276, 10.1182/blood-2007-08-106286
Sarantopoulos, 2007, High levels of B-cell activating factor in patients with active chronic graft-versus-host disease, Clin Cancer Res, 13, 6107, 10.1158/1078-0432.CCR-07-1290
Patriarca, 2006, The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery, Exp Hematol, 34, 389, 10.1016/j.exphem.2005.12.011
Young, 2012, Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease, J Immunol, 189, 222, 10.4049/jimmunol.1200677
Miklos, 2004, Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors, Blood, 103, 353, 10.1182/blood-2003-03-0984
Sahaf, 2013, H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease, Proc Natl Acad Sci USA, 110, 3005, 10.1073/pnas.1222900110
Svegliati, 2007, Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease, Blood, 110, 237, 10.1182/blood-2007-01-071043
Spies-Weisshart, 2013, Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD), J Cancer Res Clin Oncol, 139, 1397, 10.1007/s00432-013-1451-z
Jin, 2016, Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice, Blood, 127, 2249, 10.1182/blood-2015-09-668145
Sarantopoulos, 2009, Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease, Blood, 113, 3865, 10.1182/blood-2008-09-177840
Forcade, 2016, Circulating T follicular helper cells with increased function during chronic graft-versus-host disease, Blood, 127, 2489, 10.1182/blood-2015-12-688895
Knorr, 2016, Loss of T follicular helper cells in the peripheral blood of patients with chronic graft-versus-host disease, Biol Blood Marrow Transplant, 22, 825, 10.1016/j.bbmt.2016.01.003
Duffield, 2005, Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair, J Clin Invest, 115, 56, 10.1172/JCI200522675
Gangadharan, 2008, Murine gammaherpesvirus-induced fibrosis is associated with the development of alternatively activated macrophages, J Leukoc Biol, 84, 50, 10.1189/jlb.0507270
Alexander, 2014, CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease, J Clin Invest, 124, 4266, 10.1172/JCI75935
Erbel, 2014, IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis, J Immunol, 193, 4344, 10.4049/jimmunol.1400181
Clancy, 2003, Clearance of apoptotic cells: TGF-beta in the balance between inflammation and fibrosis, J Leukoc Biol, 74, 959, 10.1189/jlb.0603276
Clancy, 1976, The effect of neonatal rat graft-vs-host disease (GVHD) on Fc receptor lymphocytes, J Immunol, 116, 210, 10.4049/jimmunol.116.1.210
Hechinger, 2015, Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD, Blood, 125, 570, 10.1182/blood-2014-06-581793
Dubovsky, 2014, Ibrutinib treatment ameliorates murine chronic graft-versus-host disease, J Clin Invest, 124, 4867, 10.1172/JCI75328
Flynn, 2015, Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease, Blood, 125, 4085, 10.1182/blood-2014-08-595470
Johnston, 2014, Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects, Biol Blood Marrow Transplant, 20, 1089, 10.1016/j.bbmt.2014.04.028
Ohkura, 2013, Development and maintenance of regulatory T cells, Immunity, 38, 414, 10.1016/j.immuni.2013.03.002
Arpaia, 2015, A distinct function of regulatory T cells in tissue protection, Cell, 162, 1078, 10.1016/j.cell.2015.08.021
Sage, 2016, T follicular regulatory cells, Immunol Rev, 271, 246, 10.1111/imr.12411
Sakaguchi, 1995, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases, J Immunol, 155, 1151, 10.4049/jimmunol.155.3.1151
Rezvani, 2006, High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT, Blood, 108, 1291, 10.1182/blood-2006-02-003996
Robb, 2012, Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation, Blood, 119, 5898, 10.1182/blood-2011-12-396119
Zhang, 2013, Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo, J Immunol, 191, 5291, 10.4049/jimmunol.1301181
Edinger, 2003, CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation, Nat Med, 9, 1144, 10.1038/nm915
Taylor, 2002, The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality, Blood, 99, 3493, 10.1182/blood.V99.10.3493
Zorn, 2005, Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease, Blood, 106, 2903, 10.1182/blood-2005-03-1257
Rieger, 2006, Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD, Blood, 107, 1717, 10.1182/blood-2005-06-2529
Matsuoka, 2010, Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation, J Clin Invest, 120, 1479, 10.1172/JCI41072
Alho, 2016, Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD, Blood, 127, 646, 10.1182/blood-2015-10-672345
Kawano, 2011, Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation, Blood, 118, 5021, 10.1182/blood-2011-06-362137
Suffner, 2010, Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice, J Immunol, 184, 1810, 10.4049/jimmunol.0902420
Coghill, 2013, CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease, Blood, 122, 825, 10.1182/blood-2012-06-435735
Leveque-El Mouttie, 2016, Corruption of dendritic cell antigen presentation during acute GVHD leads to a failure of regulatory T-cell homeostasis and chronic GVHD, Blood, 128, 794, 10.1182/blood-2015-11-680876
Blair, 2010, CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients, Immunity, 32, 129, 10.1016/j.immuni.2009.11.009
Iwata, 2011, Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells, Blood, 117, 530, 10.1182/blood-2010-07-294249
Kheav, 2014, Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation, Haematologica, 99, 1860, 10.3324/haematol.2014.108407
Cooley, 2009, Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia, Blood, 113, 726, 10.1182/blood-2008-07-171926
Noval Rivas, 2010, NK cell regulation of CD4 T cell-mediated graft-versus-host disease, J Immunol, 184, 6790, 10.4049/jimmunol.0902598
Zecher, 2010, NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells, J Immunol, 184, 6649, 10.4049/jimmunol.0903729
Palmer, 2013, Clinical relevance of natural killer cells following hematopoietic stem cell transplantation, J Cancer, 4, 25, 10.7150/jca.5049
Inamoto, 2011, Treatment of chronic graft-versus-host disease in 2011, Curr Opin Hematol, 18, 414, 10.1097/MOH.0b013e32834ba87d
Flowers, 2008, A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease, Blood, 112, 2667, 10.1182/blood-2008-03-141481
Martelli, 2014, HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse, Blood, 124, 638, 10.1182/blood-2014-03-564401
Robinson, 2016, Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide, Semin Hematol, 53, 90, 10.1053/j.seminhematol.2016.01.005
Yu, 2011, Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice, Blood, 118, 5011, 10.1182/blood-2011-03-340315
Cohen, 2002, CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease, J Exp Med, 196, 401, 10.1084/jem.20020090
Hoffmann, 2002, Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation, J Exp Med, 196, 389, 10.1084/jem.20020399
Di Ianni, 2011, Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation, Blood, 117, 3921, 10.1182/blood-2010-10-311894
Brunstein, 2016, Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect, Blood, 127, 1044, 10.1182/blood-2015-06-653667
McDonald-Hyman, 2016, Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner, Blood, 128, 1013, 10.1182/blood-2016-05-715896
Koreth, 2016, Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease, Blood, 128, 130, 10.1182/blood-2016-02-702852
Koreth, 2011, Interleukin-2 and regulatory T cells in graft-versus-host disease, N Engl J Med, 365, 2055, 10.1056/NEJMoa1108188
Cutler, 2013, Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial, Blood, 122, 1510, 10.1182/blood-2013-04-495895
Arai, 2016, A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation, Clin Cancer Res, 22, 319, 10.1158/1078-0432.CCR-15-1443
Spoerl, 2014, Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease, Blood, 123, 3832, 10.1182/blood-2013-12-543736
Zeiser, 2015, Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey, Leukemia, 29, 2062, 10.1038/leu.2015.212
Pai, 2014, Treatment of chronic graft-versus-host disease with bortezomib, Blood, 124, 1677, 10.1182/blood-2014-02-554279
Banovic, 2005, TGF-beta in allogeneic stem cell transplantation: friend or foe?, Blood, 106, 2206, 10.1182/blood-2005-01-0062